 Ivor Douglas
Concepts (602)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration, Artificial | 24 | 2025 | 643 | 3.760 |
Why?
| | Sepsis | 23 | 2025 | 611 | 3.260 |
Why?
| | Fluid Therapy | 14 | 2025 | 147 | 2.880 |
Why?
| | Respiratory Insufficiency | 12 | 2023 | 316 | 2.320 |
Why?
| | Critical Care | 19 | 2025 | 584 | 2.220 |
Why?
| | Critical Illness | 20 | 2025 | 809 | 2.060 |
Why?
| | Intensive Care Units | 24 | 2025 | 803 | 2.000 |
Why?
| | Tracheostomy | 5 | 2024 | 132 | 1.740 |
Why?
| | Shock, Septic | 11 | 2024 | 221 | 1.560 |
Why?
| | Hospital Mortality | 19 | 2024 | 902 | 1.500 |
Why?
| | Hypotension | 6 | 2025 | 123 | 1.460 |
Why?
| | Shock | 3 | 2024 | 95 | 1.440 |
Why?
| | Resuscitation | 11 | 2025 | 250 | 1.370 |
Why?
| | Vasoconstrictor Agents | 7 | 2025 | 138 | 1.300 |
Why?
| | Hospitals | 6 | 2023 | 678 | 1.260 |
Why?
| | Pneumonia | 7 | 2023 | 638 | 1.130 |
Why?
| | Resuscitation Orders | 3 | 2023 | 44 | 1.010 |
Why?
| | Multiple Organ Failure | 4 | 2024 | 127 | 0.960 |
Why?
| | Humans | 138 | 2025 | 137514 | 0.860 |
Why?
| | Patient Readmission | 6 | 2021 | 696 | 0.860 |
Why?
| | Ultrasonography, Doppler | 1 | 2024 | 123 | 0.830 |
Why?
| | Middle Aged | 61 | 2025 | 33355 | 0.820 |
Why?
| | Aged | 48 | 2025 | 23798 | 0.820 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2015 | 53 | 0.800 |
Why?
| | Safety-net Providers | 3 | 2023 | 117 | 0.740 |
Why?
| | Hospitals, High-Volume | 2 | 2019 | 44 | 0.740 |
Why?
| | Hemodynamics | 3 | 2024 | 1114 | 0.720 |
Why?
| | Monitoring, Physiologic | 4 | 2024 | 267 | 0.710 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2838 | 0.710 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2023 | 292 | 0.700 |
Why?
| | Male | 76 | 2025 | 67718 | 0.690 |
Why?
| | Patient Acceptance of Health Care | 5 | 2021 | 809 | 0.680 |
Why?
| | Frailty | 1 | 2023 | 169 | 0.670 |
Why?
| | Diabetes Insipidus | 1 | 2020 | 6 | 0.670 |
Why?
| | Retrospective Studies | 31 | 2025 | 15628 | 0.670 |
Why?
| | Patient Positioning | 1 | 2021 | 68 | 0.670 |
Why?
| | Practice Guidelines as Topic | 6 | 2021 | 1580 | 0.640 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2021 | 179 | 0.630 |
Why?
| | Hospitals, Low-Volume | 1 | 2019 | 22 | 0.620 |
Why?
| | Noninvasive Ventilation | 4 | 2025 | 51 | 0.600 |
Why?
| | Dyspnea | 2 | 2021 | 251 | 0.580 |
Why?
| | Female | 67 | 2025 | 73162 | 0.580 |
Why?
| | Acute Kidney Injury | 8 | 2025 | 811 | 0.580 |
Why?
| | Delirium | 3 | 2025 | 85 | 0.550 |
Why?
| | Adult | 44 | 2025 | 37821 | 0.540 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 8 | 2025 | 1042 | 0.540 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1035 | 0.540 |
Why?
| | Ventilator-Induced Lung Injury | 3 | 2018 | 59 | 0.520 |
Why?
| | Alcoholism | 5 | 2021 | 805 | 0.520 |
Why?
| | Pulmonary Medicine | 3 | 2015 | 85 | 0.510 |
Why?
| | California | 5 | 2022 | 425 | 0.510 |
Why?
| | Microbiological Techniques | 1 | 2016 | 30 | 0.500 |
Why?
| | Sleep Medicine Specialty | 1 | 2015 | 10 | 0.490 |
Why?
| | Acute Lung Injury | 6 | 2023 | 288 | 0.480 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 104 | 0.470 |
Why?
| | Hyperemia | 3 | 2024 | 49 | 0.460 |
Why?
| | Neoplasms | 3 | 2023 | 2666 | 0.460 |
Why?
| | Health Policy | 4 | 2024 | 388 | 0.460 |
Why?
| | Ethanol | 2 | 2021 | 608 | 0.460 |
Why?
| | Randomized Controlled Trials as Topic | 10 | 2023 | 1465 | 0.450 |
Why?
| | Research Design | 9 | 2023 | 1116 | 0.430 |
Why?
| | Aged, 80 and over | 13 | 2025 | 7593 | 0.420 |
Why?
| | Renin-Angiotensin System | 2 | 2025 | 84 | 0.420 |
Why?
| | Prone Position | 3 | 2021 | 30 | 0.420 |
Why?
| | Cohort Studies | 11 | 2023 | 5730 | 0.420 |
Why?
| | Receptor, EphA2 | 3 | 2018 | 19 | 0.410 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 654 | 0.410 |
Why?
| | Cause of Death | 3 | 2015 | 431 | 0.400 |
Why?
| | Immune Tolerance | 1 | 2015 | 362 | 0.400 |
Why?
| | Laryngoscopes | 2 | 2023 | 38 | 0.400 |
Why?
| | Inpatients | 3 | 2023 | 502 | 0.390 |
Why?
| | Nicotinic Agonists | 1 | 2014 | 130 | 0.390 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 26 | 0.390 |
Why?
| | Marijuana Smoking | 1 | 2015 | 250 | 0.380 |
Why?
| | Cross Infection | 5 | 2020 | 238 | 0.380 |
Why?
| | Hospitalization | 10 | 2025 | 2197 | 0.370 |
Why?
| | Apoptosis | 6 | 2014 | 2557 | 0.370 |
Why?
| | Tobacco Use Disorder | 1 | 2014 | 252 | 0.360 |
Why?
| | Lung | 12 | 2018 | 4066 | 0.360 |
Why?
| | Prospective Studies | 13 | 2025 | 7598 | 0.360 |
Why?
| | Tissue Plasminogen Activator | 2 | 2024 | 225 | 0.360 |
Why?
| | Nicotine | 1 | 2014 | 338 | 0.350 |
Why?
| | Organ Dysfunction Scores | 2 | 2024 | 47 | 0.350 |
Why?
| | Lipopolysaccharides | 4 | 2017 | 886 | 0.350 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 400 | 0.350 |
Why?
| | Immunity, Innate | 1 | 2017 | 832 | 0.350 |
Why?
| | Glycosaminoglycans | 3 | 2016 | 84 | 0.350 |
Why?
| | Protein C | 5 | 2012 | 59 | 0.340 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 363 | 0.340 |
Why?
| | Glycocalyx | 2 | 2025 | 28 | 0.340 |
Why?
| | Child Development | 1 | 2015 | 474 | 0.340 |
Why?
| | Long-Term Care | 2 | 2022 | 100 | 0.330 |
Why?
| | Treatment Outcome | 16 | 2025 | 10821 | 0.320 |
Why?
| | Antipsychotic Agents | 2 | 2024 | 196 | 0.320 |
Why?
| | Smoking Cessation | 1 | 2014 | 447 | 0.320 |
Why?
| | Emergency Service, Hospital | 5 | 2024 | 2054 | 0.310 |
Why?
| | Vena Cava, Inferior | 3 | 2024 | 71 | 0.310 |
Why?
| | Ephrin-A1 | 3 | 2018 | 4 | 0.310 |
Why?
| | Comorbidity | 4 | 2022 | 1618 | 0.310 |
Why?
| | Biomarkers | 8 | 2025 | 4172 | 0.300 |
Why?
| | Metabolic Syndrome | 2 | 2023 | 354 | 0.300 |
Why?
| | Length of Stay | 6 | 2024 | 1210 | 0.300 |
Why?
| | United States | 18 | 2024 | 14696 | 0.300 |
Why?
| | Public Health | 1 | 2014 | 579 | 0.300 |
Why?
| | Lipid A | 2 | 2014 | 29 | 0.300 |
Why?
| | Institutional Practice | 1 | 2008 | 4 | 0.300 |
Why?
| | Cannabis | 1 | 2015 | 490 | 0.290 |
Why?
| | Intubation, Intratracheal | 4 | 2024 | 259 | 0.290 |
Why?
| | Societies, Medical | 7 | 2021 | 820 | 0.280 |
Why?
| | Odds Ratio | 6 | 2019 | 1063 | 0.280 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2008 | 94 | 0.280 |
Why?
| | Betacoronavirus | 2 | 2020 | 268 | 0.280 |
Why?
| | Neutrophils | 3 | 2024 | 1238 | 0.270 |
Why?
| | Pandemics | 4 | 2024 | 1619 | 0.270 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2007 | 17 | 0.270 |
Why?
| | Integrins | 1 | 2007 | 95 | 0.270 |
Why?
| | Neovascularization, Pathologic | 2 | 2007 | 301 | 0.270 |
Why?
| | Haloperidol | 3 | 2025 | 33 | 0.260 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1800 | 0.260 |
Why?
| | MAP Kinase Signaling System | 2 | 2014 | 322 | 0.260 |
Why?
| | Patient Admission | 2 | 2023 | 191 | 0.250 |
Why?
| | Hyponatremia | 1 | 2006 | 42 | 0.250 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 50 | 0.250 |
Why?
| | Lung Injury | 3 | 2016 | 218 | 0.250 |
Why?
| | Leukocytes | 1 | 2007 | 311 | 0.250 |
Why?
| | Ultrasonography | 3 | 2024 | 750 | 0.250 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 616 | 0.240 |
Why?
| | Double-Blind Method | 9 | 2024 | 1987 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 368 | 0.240 |
Why?
| | Medicaid | 3 | 2021 | 436 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 359 | 0.240 |
Why?
| | Laryngoscopy | 2 | 2023 | 109 | 0.240 |
Why?
| | Chemokines, CXC | 1 | 2005 | 70 | 0.230 |
Why?
| | Academic Medical Centers | 3 | 2021 | 498 | 0.230 |
Why?
| | Bronchi | 1 | 2006 | 261 | 0.230 |
Why?
| | Oxazines | 1 | 2024 | 30 | 0.230 |
Why?
| | Bronchiectasis | 1 | 2006 | 111 | 0.230 |
Why?
| | Bronchiolitis Obliterans | 1 | 2005 | 69 | 0.230 |
Why?
| | Biomedical Research | 3 | 2021 | 689 | 0.230 |
Why?
| | Adrenal Insufficiency | 2 | 2013 | 32 | 0.230 |
Why?
| | Infusions, Intravenous | 5 | 2024 | 411 | 0.230 |
Why?
| | Methylprednisolone | 1 | 2005 | 85 | 0.230 |
Why?
| | Regeneration | 1 | 2006 | 195 | 0.230 |
Why?
| | Venous Pressure | 1 | 2024 | 8 | 0.220 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2016 | 103 | 0.220 |
Why?
| | Plasminogen | 1 | 2024 | 30 | 0.220 |
Why?
| | Phagocytosis | 1 | 2006 | 379 | 0.220 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 111 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 126 | 0.220 |
Why?
| | Leukocyte Elastase | 1 | 2024 | 77 | 0.220 |
Why?
| | Vasopressins | 3 | 2021 | 64 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2024 | 86 | 0.220 |
Why?
| | Respiratory Mucosa | 1 | 2006 | 324 | 0.210 |
Why?
| | Anti-Infective Agents | 4 | 2012 | 256 | 0.210 |
Why?
| | Cytokines | 7 | 2017 | 2095 | 0.210 |
Why?
| | Atrial Pressure | 1 | 2023 | 3 | 0.210 |
Why?
| | Renal Dialysis | 4 | 2023 | 434 | 0.210 |
Why?
| | beta Catenin | 1 | 2005 | 251 | 0.210 |
Why?
| | Hypoxia | 3 | 2024 | 1108 | 0.210 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2023 | 25 | 0.210 |
Why?
| | Diterpenes | 2 | 2014 | 31 | 0.210 |
Why?
| | Area Under Curve | 3 | 2020 | 316 | 0.200 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 126 | 0.200 |
Why?
| | Hemodynamic Monitoring | 1 | 2022 | 1 | 0.200 |
Why?
| | Risk Factors | 10 | 2021 | 10356 | 0.200 |
Why?
| | Lung Diseases | 3 | 2016 | 768 | 0.200 |
Why?
| | Craniocerebral Trauma | 1 | 2005 | 168 | 0.200 |
Why?
| | Thiazoles | 2 | 2024 | 123 | 0.200 |
Why?
| | Fibrinolysis | 1 | 2024 | 143 | 0.200 |
Why?
| | Fibrosis | 1 | 2005 | 552 | 0.190 |
Why?
| | Treatment Failure | 6 | 2021 | 353 | 0.190 |
Why?
| | Early Diagnosis | 4 | 2017 | 244 | 0.180 |
Why?
| | Transportation | 1 | 2022 | 53 | 0.180 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 746 | 0.180 |
Why?
| | Acetaminophen | 1 | 2024 | 269 | 0.180 |
Why?
| | Clinical Decision-Making | 1 | 2024 | 321 | 0.180 |
Why?
| | Central Nervous System Depressants | 1 | 2021 | 85 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2023 | 333 | 0.180 |
Why?
| | Logistic Models | 7 | 2017 | 2064 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2021 | 43 | 0.180 |
Why?
| | Hydrocortisone | 1 | 2003 | 318 | 0.180 |
Why?
| | Pyridines | 1 | 2024 | 508 | 0.170 |
Why?
| | Heart Arrest | 2 | 2021 | 339 | 0.170 |
Why?
| | Hospital Charges | 1 | 2020 | 43 | 0.170 |
Why?
| | Piperazines | 2 | 2024 | 351 | 0.170 |
Why?
| | Stroke Volume | 1 | 2024 | 619 | 0.170 |
Why?
| | Rib Fractures | 1 | 2020 | 32 | 0.170 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 59 | 0.170 |
Why?
| | Health Priorities | 1 | 2020 | 44 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2005 | 599 | 0.170 |
Why?
| | Community-Acquired Infections | 3 | 2020 | 172 | 0.160 |
Why?
| | Antigens, Differentiation | 1 | 2000 | 83 | 0.160 |
Why?
| | Endothelium, Vascular | 2 | 2025 | 923 | 0.160 |
Why?
| | Reproducibility of Results | 5 | 2024 | 3292 | 0.160 |
Why?
| | Internship and Residency | 2 | 2019 | 1131 | 0.160 |
Why?
| | Heart Failure | 3 | 2023 | 2222 | 0.160 |
Why?
| | Patient Handoff | 1 | 2019 | 33 | 0.160 |
Why?
| | Risk Adjustment | 1 | 2020 | 78 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2014 | 2482 | 0.160 |
Why?
| | Animals | 20 | 2018 | 37011 | 0.160 |
Why?
| | Patient Selection | 1 | 2023 | 691 | 0.160 |
Why?
| | Cell Adhesion Molecules | 1 | 2000 | 183 | 0.150 |
Why?
| | Hospital Costs | 1 | 2019 | 119 | 0.150 |
Why?
| | Dopamine Antagonists | 1 | 2018 | 26 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1241 | 0.150 |
Why?
| | Age Factors | 4 | 2019 | 3301 | 0.150 |
Why?
| | Mice, Inbred C57BL | 9 | 2018 | 5792 | 0.150 |
Why?
| | ROC Curve | 1 | 2020 | 547 | 0.140 |
Why?
| | Antimicrobial Stewardship | 1 | 2020 | 115 | 0.140 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 222 | 0.140 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 640 | 0.140 |
Why?
| | Thrombosis | 1 | 2021 | 368 | 0.140 |
Why?
| | Optometry | 1 | 2017 | 8 | 0.140 |
Why?
| | Platelet Count | 2 | 2014 | 86 | 0.140 |
Why?
| | Eosinophils | 1 | 2000 | 331 | 0.140 |
Why?
| | Caregivers | 1 | 2025 | 872 | 0.140 |
Why?
| | Tidal Volume | 2 | 2014 | 86 | 0.140 |
Why?
| | Cell Adhesion | 4 | 2012 | 467 | 0.140 |
Why?
| | Guideline Adherence | 2 | 2014 | 549 | 0.130 |
Why?
| | Health Services Accessibility | 4 | 2020 | 976 | 0.130 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2039 | 0.130 |
Why?
| | Lymphocyte Count | 1 | 2017 | 150 | 0.130 |
Why?
| | Transients and Migrants | 1 | 2017 | 27 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2020 | 1324 | 0.130 |
Why?
| | Blood Glucose | 2 | 2023 | 2183 | 0.130 |
Why?
| | Pyrimidines | 2 | 2024 | 472 | 0.130 |
Why?
| | Tretinoin | 1 | 2017 | 123 | 0.130 |
Why?
| | Nephrectomy | 2 | 2008 | 168 | 0.130 |
Why?
| | Health Insurance Exchanges | 1 | 2016 | 1 | 0.130 |
Why?
| | Risk Management | 1 | 2017 | 91 | 0.130 |
Why?
| | Cystic Fibrosis | 1 | 2006 | 1105 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 279 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 283 | 0.120 |
Why?
| | Mice | 13 | 2017 | 17843 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 948 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1047 | 0.120 |
Why?
| | Breath Tests | 1 | 2016 | 87 | 0.120 |
Why?
| | Sleep Wake Disorders | 2 | 2017 | 283 | 0.120 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1169 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2018 | 236 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 807 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2021 | 442 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 187 | 0.120 |
Why?
| | Research | 1 | 2018 | 446 | 0.120 |
Why?
| | Alcohol Withdrawal Seizures | 1 | 2014 | 1 | 0.120 |
Why?
| | Survival Analysis | 4 | 2014 | 1320 | 0.120 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2014 | 8 | 0.120 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 93 | 0.110 |
Why?
| | Staphylococcus aureus | 2 | 2011 | 452 | 0.110 |
Why?
| | Automation | 1 | 2015 | 95 | 0.110 |
Why?
| | Marriage | 1 | 2016 | 121 | 0.110 |
Why?
| | 5-Lipoxygenase-Activating Protein Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
| | 5-Lipoxygenase-Activating Proteins | 1 | 2014 | 4 | 0.110 |
Why?
| | Bacteriological Techniques | 1 | 2015 | 71 | 0.110 |
Why?
| | Heparitin Sulfate | 3 | 2025 | 50 | 0.110 |
Why?
| | Multicenter Studies as Topic | 3 | 2023 | 308 | 0.110 |
Why?
| | Leukotrienes | 1 | 2014 | 37 | 0.110 |
Why?
| | Fluorobenzenes | 1 | 2014 | 16 | 0.110 |
Why?
| | Prognosis | 5 | 2021 | 4031 | 0.110 |
Why?
| | Phenanthrenes | 1 | 2014 | 13 | 0.110 |
Why?
| | Patient Care Team | 1 | 2019 | 629 | 0.110 |
Why?
| | Risk Assessment | 5 | 2015 | 3439 | 0.110 |
Why?
| | APACHE | 2 | 2011 | 69 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 151 | 0.110 |
Why?
| | Physicians | 2 | 2021 | 904 | 0.110 |
Why?
| | Down-Regulation | 2 | 2017 | 658 | 0.110 |
Why?
| | Education, Medical | 1 | 2017 | 260 | 0.110 |
Why?
| | Alanine Transaminase | 1 | 2014 | 158 | 0.110 |
Why?
| | Catheterization, Central Venous | 1 | 2015 | 111 | 0.110 |
Why?
| | Quality of Life | 2 | 2024 | 2870 | 0.110 |
Why?
| | Poverty | 2 | 2016 | 520 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 95 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 892 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2000 | 1092 | 0.110 |
Why?
| | Laryngeal Masks | 1 | 2013 | 14 | 0.110 |
Why?
| | Microscopy | 1 | 2015 | 144 | 0.100 |
Why?
| | Quinolines | 1 | 2014 | 180 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2024 | 1332 | 0.100 |
Why?
| | Time Factors | 7 | 2023 | 6817 | 0.100 |
Why?
| | Supine Position | 1 | 2012 | 39 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 552 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2017 | 527 | 0.100 |
Why?
| | Acute Disease | 3 | 2016 | 1008 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1950 | 0.090 |
Why?
| | Patient Discharge | 1 | 2018 | 895 | 0.090 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 28 | 0.090 |
Why?
| | Cisplatin | 1 | 2014 | 318 | 0.090 |
Why?
| | Data Interpretation, Statistical | 2 | 2011 | 352 | 0.090 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 81 | 0.090 |
Why?
| | Oxygen | 3 | 2023 | 943 | 0.090 |
Why?
| | Clinical Alarms | 1 | 2011 | 10 | 0.090 |
Why?
| | Data Display | 1 | 2011 | 20 | 0.090 |
Why?
| | Insurance, Health | 1 | 2014 | 282 | 0.090 |
Why?
| | Endotoxemia | 1 | 2012 | 86 | 0.090 |
Why?
| | Health Status | 1 | 2017 | 784 | 0.090 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 37 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5139 | 0.090 |
Why?
| | Albuterol | 1 | 2011 | 110 | 0.090 |
Why?
| | Indoles | 1 | 2014 | 415 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 345 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 513 | 0.080 |
Why?
| | Peroxidase | 2 | 2008 | 176 | 0.080 |
Why?
| | Fibrinolytic Agents | 2 | 2024 | 275 | 0.080 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2009 | 2 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2011 | 124 | 0.080 |
Why?
| | Recombinant Proteins | 5 | 2012 | 1357 | 0.080 |
Why?
| | Thoracic Diseases | 1 | 2009 | 14 | 0.080 |
Why?
| | Interferons | 1 | 2011 | 199 | 0.080 |
Why?
| | Clinical Protocols | 2 | 2012 | 268 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 442 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 906 | 0.080 |
Why?
| | Symptom Assessment | 2 | 2020 | 126 | 0.080 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2009 | 45 | 0.080 |
Why?
| | Survival Rate | 3 | 2015 | 1980 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1227 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 665 | 0.080 |
Why?
| | Cell Movement | 3 | 2011 | 972 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 555 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2016 | 752 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 846 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2010 | 328 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1061 | 0.080 |
Why?
| | Databases, Factual | 2 | 2016 | 1351 | 0.080 |
Why?
| | Age Distribution | 1 | 2010 | 391 | 0.080 |
Why?
| | Cues | 1 | 2011 | 335 | 0.080 |
Why?
| | Sex Distribution | 1 | 2010 | 378 | 0.080 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4295 | 0.080 |
Why?
| | Pneumonia, Bacterial | 1 | 2009 | 117 | 0.070 |
Why?
| | Pancreatitis | 1 | 2009 | 132 | 0.070 |
Why?
| | Pulmonary Alveoli | 2 | 2012 | 405 | 0.070 |
Why?
| | Work Schedule Tolerance | 1 | 2008 | 48 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2023 | 105 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 667 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2792 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2014 | 651 | 0.070 |
Why?
| | United Kingdom | 1 | 2008 | 324 | 0.070 |
Why?
| | Mandatory Programs | 1 | 2007 | 15 | 0.070 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 290 | 0.070 |
Why?
| | Demeclocycline | 1 | 2006 | 2 | 0.070 |
Why?
| | Flavonoids | 1 | 2007 | 83 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2008 | 778 | 0.070 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 272 | 0.070 |
Why?
| | Methicillin Resistance | 1 | 2006 | 18 | 0.070 |
Why?
| | Lithium Compounds | 1 | 2006 | 12 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 153 | 0.060 |
Why?
| | Workload | 1 | 2008 | 163 | 0.060 |
Why?
| | Child, Preschool | 2 | 2015 | 11097 | 0.060 |
Why?
| | Disease Progression | 4 | 2017 | 2755 | 0.060 |
Why?
| | Clinical Competence | 1 | 2014 | 1093 | 0.060 |
Why?
| | Signal Transduction | 4 | 2018 | 5096 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2501 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1995 | 1079 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 186 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2012 | 139 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 101 | 0.060 |
Why?
| | Diuretics | 1 | 2006 | 74 | 0.060 |
Why?
| | Hospitals, Urban | 2 | 2018 | 135 | 0.060 |
Why?
| | Hospital Information Systems | 1 | 2006 | 16 | 0.060 |
Why?
| | Mesoderm | 1 | 2007 | 144 | 0.060 |
Why?
| | History, 20th Century | 2 | 2017 | 324 | 0.060 |
Why?
| | Sex Factors | 3 | 2018 | 2074 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2007 | 168 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2005 | 38 | 0.060 |
Why?
| | Asparagine | 1 | 2005 | 31 | 0.060 |
Why?
| | Angiopoietin-2 | 1 | 2025 | 16 | 0.060 |
Why?
| | Mice, Inbred BALB C | 2 | 2005 | 1271 | 0.060 |
Why?
| | Vocabulary | 1 | 2006 | 46 | 0.060 |
Why?
| | Emphysema | 1 | 2006 | 109 | 0.060 |
Why?
| | Bronchoscopy | 1 | 2007 | 222 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2025 | 38 | 0.060 |
Why?
| | Cyclin D1 | 1 | 2005 | 67 | 0.060 |
Why?
| | Heparin | 1 | 2007 | 259 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 920 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2005 | 145 | 0.060 |
Why?
| | Rats | 2 | 2012 | 5676 | 0.060 |
Why?
| | Medical Order Entry Systems | 1 | 2006 | 44 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 2007 | 1903 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 188 | 0.060 |
Why?
| | Adolescent | 5 | 2025 | 21555 | 0.060 |
Why?
| | Angiotensin I | 1 | 2025 | 7 | 0.060 |
Why?
| | Occupational Health | 1 | 2008 | 208 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2615 | 0.060 |
Why?
| | Venous Thrombosis | 1 | 2007 | 187 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 13243 | 0.060 |
Why?
| | Ischemia | 1 | 2008 | 408 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1770 | 0.060 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2024 | 17 | 0.060 |
Why?
| | Necrosis | 1 | 2005 | 244 | 0.060 |
Why?
| | Androstanols | 1 | 2024 | 18 | 0.060 |
Why?
| | HMGB1 Protein | 1 | 2005 | 50 | 0.060 |
Why?
| | Caspases | 1 | 2005 | 247 | 0.060 |
Why?
| | Hope | 1 | 2024 | 23 | 0.060 |
Why?
| | Pyridazines | 1 | 2024 | 56 | 0.060 |
Why?
| | Macrophages | 2 | 2014 | 1548 | 0.050 |
Why?
| | Medicago | 1 | 2023 | 1 | 0.050 |
Why?
| | Diabetic Ketoacidosis | 1 | 2007 | 202 | 0.050 |
Why?
| | Colorado | 4 | 2017 | 4521 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 1 | 2006 | 425 | 0.050 |
Why?
| | Cadherins | 1 | 2005 | 205 | 0.050 |
Why?
| | Renal Replacement Therapy | 1 | 2024 | 92 | 0.050 |
Why?
| | Steroids | 2 | 2021 | 167 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 127 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1312 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 845 | 0.050 |
Why?
| | Atrial Function, Right | 1 | 2023 | 12 | 0.050 |
Why?
| | Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1524 | 0.050 |
Why?
| | Collagen | 1 | 2005 | 447 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 784 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1132 | 0.050 |
Why?
| | Mental Health | 2 | 2022 | 724 | 0.050 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2007 | 351 | 0.050 |
Why?
| | Homeostasis | 1 | 2006 | 622 | 0.050 |
Why?
| | Angiotensin II | 1 | 2023 | 99 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2145 | 0.050 |
Why?
| | Decision Support Techniques | 2 | 2020 | 419 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 459 | 0.050 |
Why?
| | Video Recording | 1 | 2023 | 184 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1486 | 0.050 |
Why?
| | Anticoagulants | 1 | 2007 | 665 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 356 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 1995 | 2494 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2006 | 402 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 283 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 57 | 0.050 |
Why?
| | Creatinine | 2 | 2015 | 501 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2007 | 780 | 0.050 |
Why?
| | Child | 2 | 2015 | 22037 | 0.050 |
Why?
| | Oligopeptides | 1 | 2023 | 273 | 0.040 |
Why?
| | Infant | 1 | 2015 | 9467 | 0.040 |
Why?
| | Electrocardiography | 1 | 2024 | 632 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2025 | 708 | 0.040 |
Why?
| | Antibodies | 2 | 2018 | 414 | 0.040 |
Why?
| | Perioperative Care | 1 | 2022 | 182 | 0.040 |
Why?
| | Leukotriene C4 | 1 | 2000 | 11 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2007 | 634 | 0.040 |
Why?
| | CD18 Antigens | 1 | 2000 | 26 | 0.040 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 2000 | 56 | 0.040 |
Why?
| | CD11 Antigens | 1 | 2000 | 30 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2020 | 71 | 0.040 |
Why?
| | Hemorrhage | 1 | 2005 | 723 | 0.040 |
Why?
| | Glasgow Coma Scale | 1 | 2020 | 182 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 207 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1790 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 181 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1099 | 0.040 |
Why?
| | Needs Assessment | 1 | 2021 | 368 | 0.040 |
Why?
| | Aftercare | 1 | 2001 | 210 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2017 | 1185 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2005 | 1307 | 0.040 |
Why?
| | NF-kappa B | 2 | 2018 | 694 | 0.040 |
Why?
| | Smoking | 1 | 2006 | 1639 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 158 | 0.040 |
Why?
| | Algorithms | 1 | 2006 | 1702 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 226 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5772 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2020 | 525 | 0.040 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
| | Linear Models | 1 | 2020 | 851 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 35 | 0.040 |
Why?
| | Trauma Centers | 1 | 2020 | 422 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2012 | 3020 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2006 | 1999 | 0.040 |
Why?
| | Victoria | 1 | 2017 | 17 | 0.030 |
Why?
| | History, 17th Century | 1 | 2017 | 15 | 0.030 |
Why?
| | History, 15th Century | 1 | 2017 | 12 | 0.030 |
Why?
| | History, 16th Century | 1 | 2017 | 16 | 0.030 |
Why?
| | Family | 1 | 2022 | 667 | 0.030 |
Why?
| | United Arab Emirates | 1 | 2017 | 7 | 0.030 |
Why?
| | History, Ancient | 1 | 2017 | 54 | 0.030 |
Why?
| | History, Medieval | 1 | 2017 | 47 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 357 | 0.030 |
Why?
| | Antigens, CD | 1 | 2000 | 524 | 0.030 |
Why?
| | Critical Care Outcomes | 1 | 2016 | 12 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2012 | 1060 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3205 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 662 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2025 | 854 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 211 | 0.030 |
Why?
| | Trauma Severity Indices | 1 | 2016 | 106 | 0.030 |
Why?
| | Probability | 1 | 2017 | 311 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5427 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1150 | 0.030 |
Why?
| | Refugees | 1 | 2017 | 76 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2018 | 437 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 23 | 0.030 |
Why?
| | Chemokine CXCL2 | 1 | 2014 | 43 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 593 | 0.030 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2014 | 43 | 0.030 |
Why?
| | Rosuvastatin Calcium | 1 | 2014 | 22 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 84 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2014 | 29 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1041 | 0.030 |
Why?
| | Risk | 1 | 2017 | 905 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2014 | 33 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1703 | 0.030 |
Why?
| | Creatine Kinase | 1 | 2014 | 79 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 92 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 310 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1286 | 0.030 |
Why?
| | Chondroitin Sulfates | 1 | 2014 | 35 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2014 | 158 | 0.030 |
Why?
| | Manikins | 1 | 2013 | 28 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2014 | 331 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2014 | 117 | 0.030 |
Why?
| | Liver Failure | 1 | 2014 | 94 | 0.030 |
Why?
| | Bronchial Spasm | 1 | 2013 | 6 | 0.030 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2013 | 19 | 0.030 |
Why?
| | Contraindications | 1 | 2013 | 90 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 433 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1161 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2016 | 741 | 0.030 |
Why?
| | Glucuronidase | 1 | 2012 | 45 | 0.020 |
Why?
| | Protein C Deficiency | 1 | 2012 | 12 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1408 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2013 | 84 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 87 | 0.020 |
Why?
| | Knowledge Bases | 1 | 2012 | 27 | 0.020 |
Why?
| | Intestinal Perforation | 1 | 2012 | 46 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2000 | 4206 | 0.020 |
Why?
| | Renal Insufficiency | 1 | 2014 | 157 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2014 | 274 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 533 | 0.020 |
Why?
| | Triage | 1 | 2014 | 221 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2017 | 627 | 0.020 |
Why?
| | Endothelium | 1 | 2012 | 122 | 0.020 |
Why?
| | Quality Assurance, Health Care | 1 | 2014 | 324 | 0.020 |
Why?
| | Water-Electrolyte Balance | 1 | 2011 | 34 | 0.020 |
Why?
| | Anesthesiology | 1 | 2013 | 85 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2012 | 224 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 625 | 0.020 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 71 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 561 | 0.020 |
Why?
| | General Surgery | 1 | 2013 | 170 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1122 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 202 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2012 | 816 | 0.020 |
Why?
| | Internal Medicine | 1 | 2013 | 254 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2011 | 269 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 320 | 0.020 |
Why?
| | Single-Payer System | 1 | 2009 | 2 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 112 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 593 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2857 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 326 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2011 | 690 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 683 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 370 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 489 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 914 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 849 | 0.020 |
Why?
| | Information Dissemination | 1 | 2011 | 218 | 0.020 |
Why?
| | Advisory Committees | 1 | 2010 | 220 | 0.020 |
Why?
| | Total Quality Management | 1 | 2008 | 60 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3546 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2852 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 831 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2008 | 36 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 183 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2009 | 362 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 207 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2008 | 107 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 426 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2008 | 144 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2008 | 208 | 0.020 |
Why?
| | Health Plan Implementation | 1 | 2008 | 140 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2008 | 192 | 0.020 |
Why?
| | Drug Industry | 1 | 2008 | 109 | 0.020 |
Why?
| | Chemokines | 1 | 2008 | 229 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1242 | 0.020 |
Why?
| | Acid-Base Equilibrium | 1 | 2007 | 28 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2066 | 0.020 |
Why?
| | Cost Control | 1 | 2006 | 39 | 0.020 |
Why?
| | Umbilical Veins | 1 | 2006 | 61 | 0.020 |
Why?
| | Medical Audit | 1 | 2007 | 76 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2006 | 75 | 0.020 |
Why?
| | Ketones | 1 | 2007 | 51 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 147 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 108 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2006 | 141 | 0.020 |
Why?
| | Bacillus subtilis | 1 | 2006 | 67 | 0.020 |
Why?
| | Information Management | 1 | 2006 | 18 | 0.020 |
Why?
| | Cell Count | 1 | 2006 | 321 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2006 | 386 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 1436 | 0.010 |
Why?
| | User-Computer Interface | 1 | 2006 | 159 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 252 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 302 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2193 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 514 | 0.010 |
Why?
| | Asthma | 1 | 2017 | 2290 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 443 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 2001 | 126 | 0.010 |
Why?
| | Hypothermia, Induced | 1 | 2001 | 79 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2838 | 0.010 |
Why?
| | Dopamine | 1 | 2001 | 301 | 0.010 |
Why?
| | Mass Screening | 1 | 2006 | 1264 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1285 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2001 | 498 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2398 | 0.010 |
Why?
|
|
Douglas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|